Trials / Completed
CompletedNCT04367935
Effect of Pentoxifylline on Endothelial Dysfunction in Patients With Acute Coronary Syndrome
Effect of Pentoxifylline on Endothelial Dysfunction in Patients With Acute Coronary Syndrome: A Pilot Study
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the effect of pentoxifylline administration on the status of endothelial function and oxidative stress biomarkers in patients with Acute Coronary Syndrome (ACS).
Detailed description
The study will be carried out at Ain Shams University Hospitals. Patients with ACS who meet the eligibility criteria and consent to participate in the study will be randomly allocated to either the intervention group or the control group. All participants will receive the standard pharmacologic treatment for ACS according to the applied guidelines offered by the facility. In addition, patients in the intervention group will receive Pentoxifylline tablets 400mg orally three times daily. Patient follow-up will be scheduled every 2 weeks for each patient to check the tolerability, the development of side effects, any medication change and medication adherence. Physical examination at each visit will be done by physician in attendance for all patients in both groups. A blood sample will be taken at baseline and at the end of the study after 2 months. for measurement of basic laboratory parameters (Complete Blood Count, Liver Function Tests, Kidney Function Tests ,..etc), the level of Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) as a marker for endothelial dysfunction, the level of Malondialdehyde (MDA) as a marker for oxidative stress.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pentoxifylline | Pentoxifylline tablets 400mg three times daily for 2 months |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2022-04-25
- Completion
- 2022-04-25
- First posted
- 2020-04-29
- Last updated
- 2022-09-07
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04367935. Inclusion in this directory is not an endorsement.